Express Scripts’ Value-Based Programs Save Plans $4.3B

April 9

Express Scripts said it saved enrolled plans some $4.3 billion in 2019 through its SafeGuardRx programs, which combine multiple cost- containment strategies such as value- based contracting and payments from financial guarantees.

The PBM first launched its “cure value” program in 2015 for hepatitis, shortly after the FDA approved Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir), the first among a slate of pricey second-generation hepatitis C therapies.

0 Comments

Radar on Drug Benefits

© 2025 MMIT

Freelance Reporter

Freelance Reporter Freelance Reporter

As World Awaits Results From Remdesivir Trials, Pricing Questions Loom April 9, 2020

Extensive Savings Remain Elusive 10 Years Into Biosimilar Era With Chart: Increased Biosimilar Use Could Offer Significant Savings for Employers April 9, 2020

Related Posts

September 26

News Briefs: Sanders Touts PBM Promise in Pushing for Wegovy, Ozempic Price Cut

READ MORE

republican-and-democratic-party

September 26

Would Red or Blue Election Wins Be Better for PBMs? It’s a Tossup

READ MORE

pharmacist

September 26

Satisfaction With PBM Industry Dips to Record Low in 2024

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today